Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Xenon Pharmaceuticals Inc.XENE · Entity 2602 | EVP, Drug Discovery | March 11, 2024 | March 12, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Xenon Pharmaceuticals Inc.
Report date March 11, 2024 · Filed March 12, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.37 · Expires 2034-03-10 | Direct | 65,000 |
Reported balance
After 2024-03-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-11 · Grant · Acquired 65,000 · Balance 65,000 F1: Vesting 25% on January 1, 2025, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. |
Filing footnotes · ownership attribution and instrument terms
F1: Vesting 25% on January 1, 2025, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 11, 2024 Filed Mar 12, 2024 22:37 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $44.37 | $0.00 |
DisclosureSEC source: 0000950170-24-030236 · ownership.xml · derivative · entry 1 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Shares · 65,000 shares Expires 2034-03-10 F1 · derivative.exercise_date: Vesting 25% on January 1, 2025, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:27 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $34.18 | $0.00 |
DisclosureSEC source: 0001209191-23-018470 · doc4.xml · derivative · entry 1 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Shares · 75,000 shares Expires 2033-03-09 F1 · derivative.exercise_date: Vesting 25% on January 1, 2024 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 21:36 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-22-046017 · doc4.xml · derivative · entry 7 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 45,000 shares Expires 2028-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 21:36 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $3.10 | $0.00 |
DisclosureSEC source: 0001209191-22-046017 · doc4.xml · derivative · entry 6 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 20,000 shares Expires 2027-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 21:36 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 21,875 | $38.68 | $846,125.00 |
DisclosureSEC source: 0001209191-22-046017 · doc4.xml · nonDerivative · entry 5 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.6084 to $38.7884, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 21:36 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 35,868 | $38.08 | $1,365,853.44 |
DisclosureSEC source: 0001209191-22-046017 · doc4.xml · nonDerivative · entry 4 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,875 F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $37.5101 to $38.5029, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 21:36 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 7,257 | $38.02 | $275,911.14 |
DisclosureSEC source: 0001209191-22-046017 · doc4.xml · nonDerivative · entry 3 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,743 F1 · price: Represents the closing price of the Company's common shares on August 11, 2022 for purposes of net settlement calculations. Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 21:36 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 45,000 | $4.75 | $213,750.00 |
DisclosureSEC source: 0001209191-22-046017 · doc4.xml · nonDerivative · entry 2 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 21:36 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 20,000 | $3.10 | $62,000.00 |
DisclosureSEC source: 0001209191-22-046017 · doc4.xml · nonDerivative · entry 1 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 20:10 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $30.01 | $0.00 |
DisclosureSEC source: 0001209191-22-018440 · doc4.xml · derivative · entry 1 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Shares · 65,000 shares Expires 2032-03-09 F1 · derivative.exercise_date: Vesting 25% on January 1, 2023 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 00:32 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $6.76 | $0.00 |
DisclosureSEC source: 0001209191-22-017316 · doc4.xml · derivative · entry 12 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 40,000 shares Expires 2026-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Vesting 25% on February 9, 2017 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 00:32 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $8.40 | $0.00 |
DisclosureSEC source: 0001209191-22-017316 · doc4.xml · derivative · entry 11 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 2,500 shares Expires 2027-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Vesting 25% on January 1, 2018, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 00:32 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 31,048 | $30.54 | $948,205.92 |
DisclosureSEC source: 0001209191-22-017316 · doc4.xml · nonDerivative · entry 9 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.5161 to $30.6208, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 00:32 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 1,805 | $30.62 | $55,269.10 |
DisclosureSEC source: 0001209191-22-017316 · doc4.xml · nonDerivative · entry 8 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,048 Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 00:32 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 8,952 | $30.23 | $270,618.96 |
DisclosureSEC source: 0001209191-22-017316 · doc4.xml · nonDerivative · entry 7 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,853 F3 · price: Represents the closing price of the Company's common shares on March 4, 2022 which was converted to a Canadian dollar amount for purposes of net settlement calculations. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 00:32 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 40,000 | $6.76 | $270,400.00 |
DisclosureSEC source: 0001209191-22-017316 · doc4.xml · nonDerivative · entry 6 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 00:32 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 695 | $30.23 | $21,009.85 |
DisclosureSEC source: 0001209191-22-017316 · doc4.xml · nonDerivative · entry 5 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,805 F3 · price: Represents the closing price of the Company's common shares on March 4, 2022 which was converted to a Canadian dollar amount for purposes of net settlement calculations. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 00:32 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 2,500 | $8.40 | $21,000.00 |
DisclosureSEC source: 0001209191-22-017316 · doc4.xml · nonDerivative · entry 4 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 00:32 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $8.40 | $0.00 |
DisclosureSEC source: 0001209191-22-017316 · doc4.xml · derivative · entry 10 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 25,000 shares Expires 2027-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Vesting 25% on January 1, 2018, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 00:32 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 18,315 | $30.79 | $563,918.85 |
DisclosureSEC source: 0001209191-22-017316 · doc4.xml · nonDerivative · entry 3 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.21 to $31.0296, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 00:32 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 6,685 | $31.42 | $210,042.70 |
DisclosureSEC source: 0001209191-22-017316 · doc4.xml · nonDerivative · entry 2 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,315 F1 · price: Represents the closing price of the Company's common shares on March 3, 2022 which was converted to a Canadian dollar amount for purposes of net settlement calculations. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 00:32 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 25,000 | $8.40 | $210,000.00 |
DisclosureSEC source: 0001209191-22-017316 · doc4.xml · nonDerivative · entry 1 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 20:35 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $20.55 | $0.00 |
DisclosureSEC source: 0001209191-21-020473 · doc4.xml · derivative · entry 1 EMPFIELD JAMES R. · CIK 0001665430 · EVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Shares · 65,000 shares Expires 2031-03-11 F1 · derivative.exercise_date: Vesting 25% on January 1, 2022 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| March 12, 2020 Filed Mar 13, 2020 21:12 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $11.58 | $0.00 |
DisclosureSEC source: 0001209191-20-018969 · doc4.xml · derivative · entry 1 EMPFIELD JAMES R. · CIK 0001665430 · SVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Shares · 65,000 shares Expires 2030-03-11 F1 · derivative.exercise_date: Vesting 25% on January 1, 2021 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| September 16, 2019 Filed Sep 18, 2019 22:28 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $9.44 | $0.00 |
DisclosureSEC source: 0001209191-19-050129 · doc4.xml · derivative · entry 1 EMPFIELD JAMES R. · CIK 0001665430 · SVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires 2029-09-15 F1 · derivative.exercise_date: Vesting over 36 months, in equal amounts, on the last day of each month. Read SEC document |
| March 12, 2018 Filed Mar 13, 2018 21:44 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001171843-18-001917 · form4.xml · derivative · entry 1 EMPFIELD JAMES R. · CIK 0001665430 · SVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Shares · 45,000 shares Expires 2028-03-11 F1 · derivative.exercise_date: Vesting 25% on January 1, 2019, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| October 23, 2017 Filed Oct 24, 2017 22:44 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $3.10 | $0.00 |
DisclosureSEC source: 0001171843-17-006254 · formfour.xml · derivative · entry 1 EMPFIELD JAMES R. · CIK 0001665430 · SVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2027-10-22 F1 · derivative.exercise_date: Vesting 25% on October 23, 2018, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 21:33 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | PurchaseCommon Shares | 10,000 | $2.48 | $24,824.00 |
DisclosureSEC source: 0001171843-17-005162 · formfour.xml · nonDerivative · entry 1 EMPFIELD JAMES R. · CIK 0001665430 · SVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| March 13, 2017 Filed Mar 14, 2017 20:28 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 27,500 | $0.00 Strike: $8.40 | $0.00 |
DisclosureSEC source: 0001171843-17-001511 · f4_empfield031417.xml · derivative · entry 1 EMPFIELD JAMES R. · CIK 0001665430 · SVP, Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Shares · 27,500 shares Expires 2027-03-12 F1 · derivative.exercise_date: Vesting 25% on January 1, 2018, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.